The FDA granted orphan drug designation to zavabresib, an investigational therapy for the treatment of myelofibrosis, a rare ...
Myelofibrosis involves driver mutations causing JAK-STAT pathway activation, leading to uncontrolled cell growth and various symptoms. JAK inhibitors like Rituxan, Inrebic, Vonjo, and Ojjaara target ...
Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, today announced that OPN-2853, a ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Up until fairly ...
On January 12, NP-G2-044 (Prilukae), a novel oral fascin inhibitor earned ODD for the treatment of pancreatic cancer. This designation covers the use of the agent as monotherapy and in combination ...
The history of primary myelofibrosis dates back to 1951 and the description of four distinct clinicopathologic entities that came to be known as myeloproliferative neoplasms (MPNs): chronic myeloid ...
MorphoSys AG (NASDAQ:MOR) is reportedly facing a burgeoning safety concern surrounding pelabresib, an experimental myelofibrosis treatment. Myelofibrosis is a type of blood cancer characterized by the ...
-- CK0804 is a first in class, CXCR4(hi) Treg therapeutic designed to preferentially traffic towards its ligand CXCL12 over expressed in the bone marrow and spleen in myelofibrosis. -- CK0804 engages ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced ...
The Myelofibrosis market across the seven major markets is projected to witness substantial expansion, growing from nearly USD 2,602 million in 2025 to about USD 5,638 million by 2034, registering a ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Jain: Our topic ...
Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, today announced that OPN-2853, a bromodomain and extra-terminal motif (BET ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results